Melalong AD Cream

Melalong AD Cream

Melalong AD Cream is a prescription medication primarily used to treat melasma, a common skin condition characterized by dark brown patches on the skin, often caused by hyperpigmentation, age, and UV radiation. It is also used to treat solar lentigines, which are darkened skin patches caused by repeated sun exposure.

Uses of Melalong AD Cream

Melalong Cream is used to treat the following conditions:

• Solar lentigines (darkened skin patches caused by repeated sun exposure)
• Melasma (dark brown patches on the skin, often caused by hyperpigmentation, age, and UV radiation)

Dosage

The dosage of Melalong AD Cream varies depending on the individual’s condition and the doctor’s prescription. It is recommended to apply the cream topically to the affected area, usually at night, and wash it off in the morning.

Other Dosage

• Tretinoin Cream
• Triluma Cream
• Tretinex Cream

Side Effects

Melalong Cream may cause the following side effects:

• Redness of the skin
• An application site that burns, stings, or irritates
• Dry skin
• Skin discoloration
• Skin peeling
• Patchy appearance of skin

Precautions

Melalong AD Cream is not recommended for use in pregnant or breastfeeding women unless necessary. It is also not recommended for use in patients with a known allergy to mequinol, tretinoin, or any other inactive ingredients present along with the formulation.

Interactions

Melalong AD Cream may interact with other skincare or medicinal products. It is recommended to consult a doctor before starting the use of other products along with this medicine.

General Instructions

Make sure you follow all the instructions on the label or package insert. Do not apply more or less than recommended. Consult a doctor if you experience any undesirable side effects.

Other Details

Melalong AD Cream is not recommended for use in children, and its safety and effectiveness have not been clinically established in this age group. It is also not recommended for use in patients suffering from eczema due to the increased risk of severe irritation to the eczematous skin.